Yann Hyvert

Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial

Ludwig Kappos, Hans‐Peter Hartung, Mark S. Freedman et al. · The Lancet Neurology · 2014 · 330 citations

Life Sciences, Neurology, Neuroimmunology +4

Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers

Olaf Stüve, Per Soelberg Soerensen, Thomas Leist et al. · Therapeutic Advances in Neurological Disorders · 2019 · 94 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials

Xavier Montalbán, Patrick Vermersch, Douglas L. Arnold et al. · The Lancet Neurology · 2024 · 72 citations

Life Sciences, Neurology, Pharmacotherapy +6

Mobilise-D insights to estimate real-world walking speed in multiple conditions with a wearable device

Cameron Kirk, Arne Küderle, M. Encarna Micó-Amigo et al. · Scientific Reports · 2024 · 71 citations · Full text

Education, Physical Medicine, Movement Analysis +16

Role of the Spätzle Pro-domain in the Generation of an Active Toll Receptor Ligand

Alexander N.R. Weber, Monique Gangloff, Martin C. Moncrieffe et al. · Journal of Biological Chemistry · 2007 · 51 citations · Full text

Life Sciences, Immunology, Molecular Biology +17